UBS Group
NAVB

UBS Group’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

UBS Group’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-400
Closed -$13K – 9043
2015
Q1 		$13K Sell
400
-625
-61% -$21.2K ﹤0.01% 7456
2014
Q4 		$39K Buy
+1,025
New +$28.2K ﹤0.01% 6810

Other funds holding NAVB

BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.28B AUM 38.1% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return

UBS Group's NAVB Position: Q4 2023 in Review

UBS Group sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q4 2023, closing a stake of 149,612 shares — an estimated $13.5K sold.

UBS Group first reported a position in NAVB in Q4 2014 and held it in 36 quarters. The position peaked at $5.43M in Q3 2015. 4 funds tracked by Wall St. Rank hold NAVB as of Q4 2023.

  • UBS Group reported no remaining Navidea Biopharmaceuticals Inc. position as of Q4 2023 after selling out during the quarter.
  • UBS Group sold 149,612 Navidea Biopharmaceuticals Inc. shares in Q4 2023, an estimated $13.5K.
  • UBS Group first reported a position in Navidea Biopharmaceuticals Inc. in Q4 2014 and held it in 36 quarters.
  • UBS Group's Navidea Biopharmaceuticals Inc. position peaked at $5.43M in Q3 2015.
  • 4 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q4 2023.

Based on UBS Group's 13F filing for Q4 2023, filed 9 Feb 2024.